Senangote, Leslie Ann .
HRN: 09-50-64 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/14/2022
CO-AMOXICLAV 625MG (TAB)
06/14/2022
06/20/2022
PO
625mg
BID
Thickly MSAF, UTI
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes